Drug Shortage Report for RECOMBIVAX HB
Report ID | 43284 |
Drug Identification Number | 02243676 |
Brand name | RECOMBIVAX HB -(PRESERVATIVE FREE) |
Common or Proper name | (hepatitis B vaccine [recombinant]) |
Company Name | MERCK CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | HEPATITIS B SURFACE ANTIGEN |
Strength(s) | 10MCG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging size | 5MCG/0.5ML 1DOSE VIAL |
ATC code | J07BC |
ATC description | VIRAL VACCINES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2018-03-21 |
Actual start date | 2018-03-19 |
Estimated end date | 2020-12-31 |
Actual end date | 2020-09-10 |
Shortage status | Resolved |
Updated date | 2020-09-11 |
Company comments | Remaining doses are reserved for the public immunization program. /Les doses restantes sont réservées au programme public de vaccination. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.